Bank of America resets Hims and Hers stock price target

Hims & Hers has been 1 of the astir intimately watched names successful integer wellness this month. Between the FDA's peptide announcement, a Novo Nordisk settlement, and a flood of expert revisions, the banal has hardly had a infinitesimal to breathe.

Now Bank of America has weighed successful again. And the crushed down this latest determination is antithetic from what drove the earlier question of upgrades.

What Bank of America conscionable did

BofA Securities raised its terms people connected Hims & Hers to $32 from $30 connected April 24, portion maintaining a Neutral standing connected the shares.

The catalyst this clip was not peptides. It was the company's announcement that its level present enables providers to prescribe Eli Lilly's weight-loss medications, including Zepbound vials, KwikPen, and Foundayo, done the LillyDirect pharmacy system, according to Investing.com.

More Wall Street

• JPMorgan resets S&P 500 terms people for the remainder of 2026

• Vanguard challenges the S&P 500 arsenic a one-stop strategy

• Goldman Sachs resets Broadcom banal forecast

The expert noted that immoderate licensed healthcare nonrecreational tin prescribe to the LillyDirect pharmacy, meaning the statement is not a ceremonial exclusive partnership. Still, BofA took a "neutral-to-positive view" connected the news, saying it could "create goodwill" with Eli Lilly and that Hims is apt to proceed pursuing akin marque relationships.

This is BofA's 2nd people rise connected HIMS this month

The April 24 revision was not the archetypal clip Bank of America adjusted its presumption connected HIMS successful April. On April 16, the steadfast had already raised its terms people from $21 to $25, citing the FDA's determination to docket a July advisory committee gathering to measure respective peptides for imaginable inclusion connected the 503A Bulks List, according to 24/7 Wall St.

That archetypal rise reflected emerging optionality astir peptide therapies, wherever Hims already owns a California-based manufacturing installation acquired successful February 2025. The 2nd raise, a week later, reflected the Lilly organisation development.

Together, the 2 moves correspond a cumulative $11 summation successful BofA's people successful conscionable 8 days, portion the Neutral standing has held dependable throughout.

The favoritism matters. A rising terms people with a level standing is simply a awesome that the concern situation is improving, but not needfully that the slope is acceptable to telephone the banal a buy. BofA is acknowledging the affirmative developments without endorsing the existent terms arsenic a wide introduction point.

What the Lilly woody really means

The Lilly improvement is strategically important for Hims adjacent without a ceremonial concern label. Patients accessing Lilly's medications done Hims & Hers' level would wage the company's $149 monthly interest positive further fees and the outgo of medicine done LillyDirect, according to Investing.com. BofA noted the wide terms constituent is comparatively costly compared to alternatives.